目的通过系统评价和实验验证,探讨微小RNA(miR)-15b-3p与卵巢储备功能减退(DOR)发生发展的关系。方法计算机检索PubMed、Cochrane Library、Embase、Web of Science、万方、中国知网、中国生物医学文献数据库,获取各数据库建库至2024年1...目的通过系统评价和实验验证,探讨微小RNA(miR)-15b-3p与卵巢储备功能减退(DOR)发生发展的关系。方法计算机检索PubMed、Cochrane Library、Embase、Web of Science、万方、中国知网、中国生物医学文献数据库,获取各数据库建库至2024年11月27日miRNA与DOR相关文献,根据纳入与排除标准筛选文献后,对纳入文献进行数据提取及质量评价,通过汇总、筛选、分析获得与DOR发生相关的miRNA。随后选取2024年3月至2024年12月在佛山复星禅诚医院中医妇科就诊的DOR患者和正常卵巢储备功能(NOR)患者为研究对象,检测患者血浆miR-15b-3p表达水平。结果共获得miRNA与DOR相关文献1626篇,最终纳入文献8篇,共涉及研究对象125人,其中实验组共62人,对照组共63人。8篇纳入文献共涉及10个独立研究、5种样本类型,结果共鉴定出94个miRNA至少在两项实验中差异表达。纳入文献的纽卡斯尔-渥太华量表(NOS)平均得分7.75分。临床检测结果显示,14位DOR患者和35位NOR患者血浆样本比较,DOR组患者血浆miR-15b-3p表达水平明显降低(P<0.001)。结论miR-221-3p、miR-483-3p、miR-126-5p、miR-15b-3p、miR-140-3p等miRNA在不同地区、样本来源的DOR患者中均差异表达,其中miR-15b-3p与DOR的发生发展密切相关,可能成为DOR早期检测和靶向治疗的潜在靶点。展开更多
Advances in molecular cell biology over the last de- cade have clarified the mechanisms involved in can- cer growth, invasion, and metastasis, and enabled the development of molecular-targeted agents. To date, sorafen...Advances in molecular cell biology over the last de- cade have clarified the mechanisms involved in can- cer growth, invasion, and metastasis, and enabled the development of molecular-targeted agents. To date, sorafenib is the only molecular-targeted agent whose survival benefit has been demonstrated in two global phase 111 randomized controlled trials, and has been approved worldwide. Phase 111 clinical trials of other molecular targeted agents comparing them with sorafenib as first-line treatment agents are ongoing. Those agents target the vascular endothelial growth factor, platelet-derived growth factor receptors, as well as target the epidermal growth factor receptor, insulin- like growth factor receptor and mammalian target of rapamycin, in addition to other molecules targeting other components of the signal transduction pathways. In addition, the combination of sorafenib with standard treatment, such as resection, ablation, transarterial em- bolization, and hepatic arterial infusion chemotherapy are ongoing. This review outlines the main pathways involved in the development and progression of hepato- cellular carcinoma and the new agents that target these pathways. Finally, the current statuses of clinical trials of new agents or combination therapy with sorafenib and standard treatment will also be discussed.展开更多
Approximately 170 million people worldwide are chronically infected with hepatitis C virus(HCV).Chronic HCV infection is the leading cause for the development of liver fibrosis,cirrhosis,hepatocellular carcinoma(HCC)a...Approximately 170 million people worldwide are chronically infected with hepatitis C virus(HCV).Chronic HCV infection is the leading cause for the development of liver fibrosis,cirrhosis,hepatocellular carcinoma(HCC)and is the primary cause for liver transplantation in the western world.Insulin resistance is one of the pathological features in patients with HCV infection and often leads to development of typeⅡdiabetes.Insulin resistance plays an important role in the development of various complications associated with HCV infection.Recent evidence indicates that HCV associated insulin resistance may result in hepatic fibrosis,steatosis,HCC and resistance to anti-viral treatment.Thus,HCV associated insulin resistance is a therapeutic target at any stage of HCV infection.HCV modulates normal cellular gene expression and interferes with the insulin signaling pathway.Various mechanisms have been proposed in regard to HCV mediated insulin resistance,involving up regulation of inflammatory cytokines,like tumor necrosis factor-α,phosphorylation of insulin-receptor substrate-1,Akt,up-regulation of gluconeogenic genes like glucose 6 phosphatase,phosphoenolpyruvate carboxykinase 2,and accumulation of lipid droplets.In this review,we summarize the available information on how HCV infection interferes with insulin signaling pathways resulting in insulin resistance.展开更多
文摘目的通过系统评价和实验验证,探讨微小RNA(miR)-15b-3p与卵巢储备功能减退(DOR)发生发展的关系。方法计算机检索PubMed、Cochrane Library、Embase、Web of Science、万方、中国知网、中国生物医学文献数据库,获取各数据库建库至2024年11月27日miRNA与DOR相关文献,根据纳入与排除标准筛选文献后,对纳入文献进行数据提取及质量评价,通过汇总、筛选、分析获得与DOR发生相关的miRNA。随后选取2024年3月至2024年12月在佛山复星禅诚医院中医妇科就诊的DOR患者和正常卵巢储备功能(NOR)患者为研究对象,检测患者血浆miR-15b-3p表达水平。结果共获得miRNA与DOR相关文献1626篇,最终纳入文献8篇,共涉及研究对象125人,其中实验组共62人,对照组共63人。8篇纳入文献共涉及10个独立研究、5种样本类型,结果共鉴定出94个miRNA至少在两项实验中差异表达。纳入文献的纽卡斯尔-渥太华量表(NOS)平均得分7.75分。临床检测结果显示,14位DOR患者和35位NOR患者血浆样本比较,DOR组患者血浆miR-15b-3p表达水平明显降低(P<0.001)。结论miR-221-3p、miR-483-3p、miR-126-5p、miR-15b-3p、miR-140-3p等miRNA在不同地区、样本来源的DOR患者中均差异表达,其中miR-15b-3p与DOR的发生发展密切相关,可能成为DOR早期检测和靶向治疗的潜在靶点。
文摘Advances in molecular cell biology over the last de- cade have clarified the mechanisms involved in can- cer growth, invasion, and metastasis, and enabled the development of molecular-targeted agents. To date, sorafenib is the only molecular-targeted agent whose survival benefit has been demonstrated in two global phase 111 randomized controlled trials, and has been approved worldwide. Phase 111 clinical trials of other molecular targeted agents comparing them with sorafenib as first-line treatment agents are ongoing. Those agents target the vascular endothelial growth factor, platelet-derived growth factor receptors, as well as target the epidermal growth factor receptor, insulin- like growth factor receptor and mammalian target of rapamycin, in addition to other molecules targeting other components of the signal transduction pathways. In addition, the combination of sorafenib with standard treatment, such as resection, ablation, transarterial em- bolization, and hepatic arterial infusion chemotherapy are ongoing. This review outlines the main pathways involved in the development and progression of hepato- cellular carcinoma and the new agents that target these pathways. Finally, the current statuses of clinical trials of new agents or combination therapy with sorafenib and standard treatment will also be discussed.
基金Supported by The National Institutes of Health,NO.DK080812
文摘Approximately 170 million people worldwide are chronically infected with hepatitis C virus(HCV).Chronic HCV infection is the leading cause for the development of liver fibrosis,cirrhosis,hepatocellular carcinoma(HCC)and is the primary cause for liver transplantation in the western world.Insulin resistance is one of the pathological features in patients with HCV infection and often leads to development of typeⅡdiabetes.Insulin resistance plays an important role in the development of various complications associated with HCV infection.Recent evidence indicates that HCV associated insulin resistance may result in hepatic fibrosis,steatosis,HCC and resistance to anti-viral treatment.Thus,HCV associated insulin resistance is a therapeutic target at any stage of HCV infection.HCV modulates normal cellular gene expression and interferes with the insulin signaling pathway.Various mechanisms have been proposed in regard to HCV mediated insulin resistance,involving up regulation of inflammatory cytokines,like tumor necrosis factor-α,phosphorylation of insulin-receptor substrate-1,Akt,up-regulation of gluconeogenic genes like glucose 6 phosphatase,phosphoenolpyruvate carboxykinase 2,and accumulation of lipid droplets.In this review,we summarize the available information on how HCV infection interferes with insulin signaling pathways resulting in insulin resistance.
